Abstract
A fixed-dose combination of losartan/hydrochlorothiazide (HCTZ) therapy may be a logical choice for antihypertensive treatment, including for initial therapy in patients with blood pressure elevation >20/10 mmHg above treatment target. The renin-angiotensin-aldosterone-system-activating effect of hydrochlorothiazide augments the efficacy of blocking the angiotensin II type 1 (AT) receptor with losartan. Some adverse effects associated with hydrochlorothiazide, including increased risk for new-onset diabetes mellitus, may be offset by losartan. Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group. The efficacy, tolerability, and convenience of losartan/HCTZ combination therapy may increase patient compliance and lower risk for stroke, a devastating outcome in patients with hypertension.
Original language | English (US) |
---|---|
Pages (from-to) | 299-305 |
Number of pages | 7 |
Journal | Vascular Health and Risk Management |
Volume | 3 |
Issue number | 3 |
State | Published - 2007 |
Externally published | Yes |
Keywords
- Angiotensin receptor blocker
- Combination therapy
- Hydrochlorothiazide
- Hypertension
- Stroke
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Hematology
- Public Health, Environmental and Occupational Health
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)